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Summary The ability of 1,9-dideoxyforskolin (DDF), 1-deoxyforskolin (DF) and forskolin to modulate
cellular sensitivity to vinblastine (VBL) was examined in drug-sensitive parental KB-3-1 cells and a multidrug-
resistant subline, KB-GRC1, derived by transfection of mdrl. Fifty gM DF and forskolin enhanced the 1 h
uptake of VBL by 8.0 ± 0.7 (s.d.) and 4.7 ± 2.5-fold, respectively, with 501lM DDF producing a 13.6 ± 1.9-
fold increase. The greater effect of DDF relative to forskolin indicated that the effect was independent of
activation ofcAMP, and this was supported by a lack ofeffect ofdibutyryl cAMP on the uptake. The effect of
these agents on uptake were < 1.4-fold in KB-3-1 cells. DDF selectively inhibited initial efflux in cells
expressing a functional P-glycoprotein (PGP), but both forskolin and DDF inhibited the terminal phase of
efflux irrespective of PGP expression. Neither agent affected membrane permeability of polarisation and
forskolin did not enhance the uptake of VBL in protein-free liposomes. At a non-toxic concentration of20 yM,
DDF and forskolin decreased the IC50 of VBL from 18.9 to 2.7 and 13 nm in KB-GRC1 cells, respectively,
and DDF acted synergistically with VBL as shown by median effect analysis [combination index = 0.20 ± 0.05
(s.d.)]. In contrast, these diterpenes did not affect VBL sensitivity in KB-3-1 cells. These results indicate that
the diterpenes modulate VBL sensitivity predominantly by inhibiting PGP-mediated efflux activity.
The concept that tumour cell sensitivity to anticancer drugs
can be regulated by activation of signal transduction path-
ways has been established (Abraham et al., 1990; Howell et
al., 1991). The protein kinase A and C pathways have been
reported to regulate sensitivity to drugs that participate in
the MDR3 phenotype (Abraham et al., 1990; Fine et al.,
1988; Hamada et al., 1987). Wadler & Wiernik (1988) dem-
onstrated that the diterpene, forskolin, a stimulator of
adenylyl cyclase which catalyses formation of cAMP
(Laurenza et al., 1989), and its inactive analogue, DDF,
partially reversed resistance to doxorubicin in murine sar-
coma S180 cells. Experiments aimed at examining the effect
of the diterpenes on doxorubin efflux showed no change in
the rate of initial efflux, and inconsistent effects on terminal
efflux in either drug-resistant or -sensitive cells. Thus, their
data suggested involvement of both cAMP-dependent and
-independent mechanisms for the reversal of resistance, but
these mechanisms were not elucidated nor were they
definitively linked with modulation of the mdrl gene product,
PGP.
Forskolin and DDF are known to inhibit the activity of
the glucose transporter, and of cholinergic and gabaminergic
ion channels, all of which share a membrane-spanning
homology with PGP (Laurenza et al., 1989). Furthermore,
adenylyl cyclase and PGP are structurally similar (Krupinski
et al., 1989). These findings have stimulated further interest
in studying forskolin and DDF as modulators of drug sen-
sitivity. During the course of this study, Morris and
coworkers (1991) reported that forskolin and DDF selectively
enhanced the cytotoxicity of doxorubicin in VBL-resistant
SKLVLB cell lines in vitro and correlated the enhanced
toxicity with the ability of photoactive analogues of forskolin
to interact directly with PGP.
We chose to examine the role of cAMP in modulating the
uptake and efflux of another substrate that participates in the
MDR phenotype, VBL, employing a well-defined MDR cell
line (Juranka et al., 1989), examining the effect of the
diterpenes on the efflux pumping activity of PGP. The cell
model chosen utilised an MDR variant, KB-GRC1, and its
drug-sensitive parental cell line, KB-3-1. KB-GRC1 cells
were derived from KB-3-1 cells by transfection of the mdrl
gene (Choi et al., 1988), and theoretically differ from KB-3-1
only by expression of PGP following the transfection (Choi
et al., 1988). KB-GRC1 cells are 67, 9.4, 4.5. and 1.5-fold
cross-resistant to VBL, doxorubicin, colchicine and etopo-
side, respectively, (ibid., Shalinsky et al., 1990a). This model
should lack the confounding influence of other changes
(Chabner & Fojo, 1989), besides overexpression of mdrl, that
occur in cells selected for VBL resistance in vitro, enabling a
direct comparison of the effect of PGP on the modulatory
abilities of the diterpenes. We report here that the primary
mechanism by which DDF and forskolin modulate VBL
sensitivity is by inhibition of a rapidly-acting PGP efflux
transporter.
Materials and methods
Drugs and chemicals
DDF, DF, and forskolin were purchased from Sigma
Chemical Co. (St. Louis, MO). Stock solutions of these drugs
were made by dissolving them in DMSO. TPP+ (97% pure)
was purchased from Aldrich Chemical Co. (Milwaukee, WI).
Working solutions were prepared by further dilution in tissue
culture medium. ['4C]-doxorubicin HCl (55 mCi mmol -) and
[3H]-TPP+ (23 Ci mmol-') were purchased from Amersham
Radiopharmaceuticals Inc. (Arlington Heights, IL) and
stored at - 20'C in saline and ethanol, respectively. [3H]-
DEP was synthesised as described by Eastman (1983).
[3H]-VBL (10-20Cimmol'1) in methanol was purchased
under a special quality-control contract to ensure high purity
from Moravek Biochemicals (Brea, CA), stored in the dark
at - 80'C and protected from light during experiments. The
purity of [3H]-VBL was confirmed by HPLC analysis accord-
ing to the method of Thimmaiah and Sethi (1985). [3H]-VBL
was stable under the experimental conditions of these studies.
The final specific activity of [3H]-VBL was 6.67mCiltmol'
for drug accumulation studies.
Cell lines and culture medium
The drug sensitive KB-3-1 line and its multidrug resistant
subline, KB-GRC1, were obtained from Dr Igor Roninson
(University of Illinois, College of Medicine, Chicago, IL).
The KB-GRC1 line was derived by transfection of the wild-
type mdrl gene coupled to a Moloney Murine Leukemia
Virus long terminal repeat into KB-3-1 cells (Choi et al.,
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1988), and are classically multidrug resistant (ibid., Shalinsky
et al., 1990a).
Mouse L cell variants, KK, MM and NEO (Morse &
Roninson, 1990), were also obtained from Dr Roninson. KK
cells were produced by transfection of the human wildtype
mdrl gene into parental fibroblast L cells. MM cells were
produced by transfection of a non-functional form of the
mdrl gene containing mutations at the ATP binding sites
into parental fibroblast cells; specifically, lysine was mutated
to methionine at positions 433 and 1,076 in the amino acid
sequence. NEO cells were produced by transfection of the
vector without the mdrl insert into parental fibroblast cells
and represented the transfectant control cell line. Over-
expression of functional and non-functional PGP in these cell
lines was confirmed by staining with the monoclonal P-
glycoCHEKR C219 antibody (Centocor, Inc., Malvern, PA).
L cell variants were grown in the presence of 0.4 mg ml-'
G-418 sulfate. Routine culture conditions have been
previously described (Shalinsky et al., 1990a).
Modulation ofcellular pharmacology
Six nM [3H]-VBL and DDF, DF or forskolin (501M or as
noted) were added to subconfluent cultures in 60-mm dishes
in 2 ml of culture medium equilibrated overnight in the CO2
incubator. Uptake was determined as previously described
(Shalinsky et al., 1993). Briefly, aliquots of a subsequently
homogenised cellular suspension were used for determination
of protein content and cell-associated radioactivity.
Efflux was determined after loading the cells with 6 nM
[3H]-VBL for 2 h until steady-state had been reached. Efflux
was monitored from 30 s to 3 h as previously described
(ibid.). The per cent of intracellular VBL that was protein-
bound was also determined as previously described (ibid.).
Cytotoxicity assays
Cytotoxicity was measured using a continuous exposure col-
ony forming assay as previously described (Shalinsky et al.,
1990a). Log-phase cells were harvested, washed and plated in
60 mm tissue culture dishes at a density of 200 cells/dish in
5 ml of culture medium. Drugs or control vehicle were added
usually as < 50Al of stock solution. Resulting colonies were
stained with Giemsa dye in methanol. Control dishes usually
contained 75-150 colonies.
Median effect analysis of the nature of the interaction
between DDF and VBL was performed as previously des-
cribed (ibid.). This analysis yields the combination index, a
measure of the extent of synergy, additivity or antagonism at
various levels of cell kill (Chou & Talalay, 1984).
Regression analysis
The apparent unidirectional influx and initial efflux rate in
KB-GRC1 and KB-3-1 cells was linear up to 240 s (r2>0.90) The rate constant for initial efflux was determined by fitting a
line to the efflux data over the first 240 s of efflux. Several
experiments, or runs, were performed under the same com-
bination of cell line and condition (control, DDF or for-
skolin); the equation for the i-th run was Ci(t) = Ai [1-ket], where Ci(t) is the concentration of VBL at any time t, Ai is
the initial concentration of VBL at C,, prior to efflux, as
shown by the fitted y-intercept, and k, is the rate constant for
initial efflux. Simultaneous fitting of the data from all runs
was done to obtain a single estimate of ke; its standard error
and degrees of freedom appeared in the regression output. The r2 values for initial efflux fittings ranged from 0.91 to
0.96 across the various combinations of cell line and condi-
tion. Similarly, for each combination of cell line and condi-
tion, the rate constant for influx was determined by fitting a
line to the influx data over the first 120 s of influx. The
equation for the i-th run was Ci(t) = Ai [1 + kint], where Ci(t) is the time zero binding of VBL, as shown by the fitted
y-intercept, and kin is the rate constant for initial uptake, i.e., influx. The r2 values for influx fittings ranged from 0.94 to
0.99 across the various combinations of cell line and condi-
tion. The fitted rate constants for efflux and influx were
compared between control and experimental groups using the
Satterwaite modification of Student's t test.
Statisticalanalysis
Unless otherwise noted, the data were expressed as the group
mean ± s.d. of duplicate determinations from each of n
experiments. The Student's t test for grouped data was used
unless otherwise stated. In all cases, significance was at the
level of P<0.05.
Results
Comparison ofditerpenes as modulators
Figure 1 compares the structure of forskolin, DF and DDF, which differ from each other by virtue of either one or two hydroxyl groups at the one and nine positions. Hydro- philicity increases with the number of hydroxyl groups with forskolin being most hydrophilic, DF intermediate and DDF least hydrophilic (K. Seamon, personal communication). Figure 2 shows the effect of increasing concentrations of DDF on the 1 h uptake of 6 nM [3H]-VBL. We have
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Figure 2 Effect of increasing concentrations of DDF on the 1 h uptake of 6 nM [3H]-VBL in KB cells. Values are mean ± s.d. of 3-4 experiments. Vertical bars, s.d.; when s.d.<size of symbol, no bar is shown.
previously shown that steady-state plateau is reached by 1 h
under control conditions (Shalinsky et al., 1990a). In KB-
GRC1 cells, 1-1I100M DDF produced a marked increase in
the uptake with an EC50 of about 15 JAM. In contrast, DDF
produced a 1.4-fold increase in the 1 h uptake in parental
KB-3-1 cells. In subsequent studies, a 50 JAM concentration of
diterpene analogue was chosen for modulation of [3H]-VBL
uptake. This concentration did not alter cellular ability to
exclude trypan blue. Figure 3 shows the time course of the
uptake under control conditions and in the presence ofDDF,
DF or forskolin. Several points are evident. First, the large
decrease in uptake in the KB-GRC1 relative to the KB-3-1
cell line confirmed the over-expression of a wildtype PGP in
the KB-GRCI cells. Second, the effects of the diterpenes
were greater in the KB-GRCI cells with DDF, DF and
forskolin enhancing VBL content at 1 h by 13.6 ± 1.9,
8.0 ± 0.7 and 4.7 ± 2.5-fold, respectively. In contrast, the
same agents produced only a 1.4 ± 0.3, 1.3 ± 0.05 and
1.2 ± 0.04-fold increase in KB-3-1 cells, respectively. These
data demonstrate that DDF was the most potent of these
diterpenes and that PGP was a likely target for the modula-
tion.
The effect of dibutyryl cAMP (Robison et al., 1968) on
VBL uptake was examined to determine the effect of increas-
ing cAMP content independent of any other effect that for-
skolin might have. Dibutyryl cAMP did not affect the I h
uptake in either cell line at concentrations of 0.01-5.O M
(data not shown). These concentrations have been reported
to produce a maximal increase in protein kinase A activity in
neoplastic cells in vitro, an increase that is sufficient to
mediate cAMP-dependent transport of other cytotoxic drugs
(Mann et al., 1991). Thus, an increase in cAMP content was
likely not required for modulation of VBL uptake, consistent
with the fact that the magnitude of DDF's effect was sub-
stantially larger than that of forskolin.
Modulation ofinflux
We have previously described the presence of a rapidly-acting
PGP efflux transporter in KB-GRC1 cells that functions to
reduce VBL uptake even during the initial seconds of
exposure (Shalinsky et al., 1990b; Shalinsky et al., 1993). In a
direct comparison between KB-GRC1 and KB-3-1 cells, the
lowered apparent influx was associated only with the
enhanced efflux in KB-GRCI, indicating that the PGP efflux
activity manifested as both reduced influx and enhanced
efflux. Thus, Figure 4 shows the apparent influx over the
initial 120 s that is due to PGP efflux activity. The ability of
PGP to reduce net accumulation was evident at times <30 s,
resulting in an approximate 2-fold decrease in the influx of
VBL in KB-GRCI cells. In KB-GRCGI cells, the diterpene
pattern of modulation was the same as in Figure 3, and all
three agents produced large increases in influx. However, there was a more pronounced effect of DDF and DF on
[3H]-VBL influx in the KB-3-1 cells than was predicated from
the magnitude of the effect of these agents at 1 h. The influx
data were well fit by a straight line (r2> 0.94). Table I shows
that DDF, DF and forskolin produced statistically significant increases in the influx rate constant in both KB-3-1 and
KB-GRC1 cells.
Modulation ofefflux
The results obtained with the KB-GRCI cells were consistent
with DDF and the diterpenes acting as inhibitors of PGP
activity. This hypothesis was tested directly by measuring the
ability of the most lipophilic compound, DDF, and the least, forskolin, to inhibit the efflux of[3H]-VBL. We employed two
cell models for these studies, including the KB cell lines, and
mouse L cell variants, transfected with either a human wild-
type, KK, or mutated and non-functional mdrl gene, MM.
L cells normally express low levels of endogenous PGP
(I.B. Roninson, personal communication) but none was
detected by flow cytometric analysis of cells stained with the
C219 antibody in the empty vector control cell line, NEO
(data not shown). VBL accumulation at 1 h was the same in
NEO and MM, but was reduced 3-fold in the KK cell line
(data not shown). Transfection of the wildtype human mdrl
gene also conferred a 5-10-fold resistance to colchicine (I.B. Roninson, personal communication) and VBL in clonogenic
assay in KK compared to NEO and MM cells (data not
shown).
The KB cell model permitted comparison of the effect of a
wildtype PGP on diterpene modulatory ability. The L cell
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model permitted assessment of the effect of wildtype or
mutated non-functional PGP on this ablity. Figure 5 shows
the efflux of [3H]-VBL in the KB cell lines. Examination of
this figure indicates that efflux was biphasic in the KB-GRC1
cells and was more rapid and of a greater extent in KB-
GRC1 than KB-3-1 cells. In KB-GRCI cells, DDF and
forskolin retarded the terminal phase of efflux. The extent of
the initial inhibition was determined by regression analysis of
the efflux data over the first 240 s of efflux. These data were
well fit by a straight line (ri>0.91). As shown in Table II,
DDF significantly inhibited the initial efflux of VBL by 34%
to 53% in each cell line expressing a wildtype form of PGP.
Forskolin inhibited initial efflux in KB-GRC1 cells but the
inhibition was not statistically significant. In KB-3-1- cells,
there was no effect on initial efflux. Figure 6 shows the effect
of these agents on efflux in the L cell variants. Increased
efflux occurred in KK cells containing the wildtype mdrl
relative to MM cells containing the mutant mdrl, estab-
lishing the viability of the L cell model for monitoring PGP-
mediated efflux. In this model, DDF inhibited initial efflux
uniquely in KK cells, but DDF and forskolin retarded ter-
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Figure 3 Time course for uptake of [3H]-VBL in KB cells in the
presence of 50AM diterpene analogue. Uptake was monitored in
KB-GRCI (0, control; *, modulator) and KB-3-1 cells (0,
control; *, modulator) as indicated. Values are mean ± s.d. of
3-4 experiments (vertical bars, s.d.; no bar is shown when
s.d. <size of symbol).
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Table I Rate constants for influx of VBL over the first 120 s
Cell Rate constant ± s.e.a P-value against
line Modulator ( x 10- sec-') control
KB-GRCI Control 0.260b + 0.017
Dipyridamolec 1.576 ± 0.297 0.002
DDF 3.156 + 0.143 <0.00001
DF 1.683 ± 0.047 <0.000001
Forskolin 0.916 + 0.083 <0.0001
KB-3-1 Control 1.634 + 0.053
Dipyridamole 3.413 + 0.372 0.013
DDF 3.593 ± 0.228 <0.0001
DF 4.162 +0.156 <0.00001
Forskolin 2.318 + 0.065 <0.00001
aValues are mean ± s.e. from three experiments. bKB-GRC1 vs
KB-3-1 control: P-value = 0.000000001. cDipyridamole data has been
included for comparison with diterpene data. Data were obtained over
20 s (Shalinsky et al., 1993).
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Figure 4 Time course for influx of [3H]-VBL in KB cells in the
presence of 50ALM diterpene analogue. Uptake was monitored for
2.0 min in KB-GRC1 (0, control; *, modulator) and KB-3-1
cells (0, control; 0, modulator) as indicated. Values are
mean ± s.d. of 3-4 experiments (vertical bars, s.d.).
12
10
12
10
8-
6-
4.
2-
0 1
12 -
10 -
8 -
6-
4-
2-
r i
c
.5
0
0-
0)
-
E
0.
E
0
0._
Co
-.
C)
E
-J
ro
E
._
0.
CL
o
.5
Q
0)
E
E5
E
0.
u Y.
I I I I IDITERPENE MODULATION OF VBL SENSITIVITY 475
Table II Rate constants for initial efflux of VBL over the first 240 s
Cell Rate constant ± s.e.a P-value against
line Modulator (min-) control
I. KB Cells
KB-GRCI Controlb 0.122 ± 0.011
Dipyridamolec 0.74 + 0.013 0.009
DDF 0.81 ±0.012 0.021
Forskolin 0.95 ± 0.013 0.129
KB-3-1 Control 0.034 ± 0.009
Dipyridamole 0.030 ± 0.005 0.193
DDF 0.034 + 0.012 0.981
Forskolin 0.025 + 0.009 0.526
II. L Cells
KK Controld 0.158 ± 0.023
Dipyridamole 0.069 ± 0.020 0.008
DDF 0.074 0.032 0.046
Forskolin not done
MM Control 0.073 + 0.016
Dipyridamole 0.058 ± 0.008 0.446
DDF 0.058 ± 0.014 0.487
Forskolin 0.067 ± 0.023 0.846
aValuesaremean ± s.e. from 3 -6experiments. bKB-GRC1 vsKB-3-1
control: P-value = 0.002. CDipyridamole data has been included for
comparison with diterpene data. Data was obtained over 2 min
(Shalinsky et al., 1993). dKK vs MM control: P-value <0.001.
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Figure 6 Efflux of [3H]-VBL in mouse L cells in the presence of
50gM diterpene analogue. Efflux was monitored for up to 90 min
under control conditions (0), or in the presence of DDF (A),
forskolin (0), or dipyridamole (M, dotted line). Values are
mean ± s.d. of 3-4 experiments (vertical bars, s.d.).
minal efflux in both cell lines. Dipyridamole was used in
these studies as a positive control to show the effect of an
MDR modulator that acts predominantly by inhibiting PGP-
mediated efflux (Shalinsky et al., 1990a; Shalinsky et al.,
180 1991; Shalinsky et al., 1993). Hence, only DDF produced a
significant inhibition of initial efflux and did so in sublines
expressing the wildtype mdrl gene, demonstrating that the
mechanism of increased uptake was due to inhibition of
PGP-mediated efflux. The fact that both DDF and forskolin
slowed the efflux of VBL by at least 1.5-fold during the
terminal phase irrespective of the presence of PGP raised the
possibility that the diterpenes were altering the intracellular
binding of VBL. Measurement of the extent of bound intra-
-0 cellular VBL demonstrated that 60% of the radiolabel was
ultrafiltrable after a I h incubation with [3H]-VBL. Forskolin
and DDF did not change the level of ultrafiltrable [3H]-VBL
(n = 2, data not shown), indicating that the diterpene effect
on uptake was not due to a change in a tightly-bound
fraction of VBL. Overall, these data indicated that DDF was
indeed inhibiting PGP efflux activity, but also pointed to
other mechanisms to account for effects on terminal efflux in
cells lacking functional PGP.
180
Time (min)
Figure 5 Efflux of [3H]-VBL in KB cells in the presence of 50jM
diterpene analogue. Efflux was monitored for up to 3 h under
control conditions (0), or in the presence of DDF (A) or
forskolin (0). Values are mean ± s.d. of 3-6 experiments (ver-
tical bars, s.d.).
Diterpene modulation of various chemotherapeutic agents
We further examined DDF's effect on the uptake of another
substrate of PGP, ['4C]-doxorubicin, and two agents, [3H]-
methotrexate and [3H]-DEP [a cisplatin analogue], which are
not (Juranka et al., 1989). These data confirmed that DDF
was selective in its modulatory ability toward MDR drugs.
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Figure 7 shows that similarly to its effect on [3H]-VBL, DDF
increased doxorubicin uptake in KB-GRC1 cells. The 35%
increase indicated that the wildtype form of PGP was much
more specific for VBL than doxorubicin. In contrast in KB-
3-1 cells, DDF failed to alter doxorubicin uptake, nor did it
elevate the uptake of [3H]-methotrexate or [3H]-DEP in either
cell line. Thus, DDF did not affect the uptake of either of the
two drugs that do not participate in the MDR phenotype.
Assessment ofnon-specific diterpene effects
Since DDF and DF stimulated VBL influx in KB-3-1 cells,
further experiments were conducted to examine whether the
enhancement may have been due to nonspecific membrane
permeabilisation. DDF and forskolin had no affect on mem-
brane permeability to propidium iodide as assessed by FACS
analysis in the same cell suspension in which the membrane
permeant, digitonin, produced a marked increase (data not
shown). Liposomes were also employed as previously des-
cribed (Shalinsky et al., 1993) to assess the effect of forskolin
on VBL uptake across a protein-free membrane. Forskolin
was inactive as a modulator in liposomes over a 2 h period
(data not shown). Finally, the 2 h uptake of the cation
[3H]-TPP+ was measured in KB-3-1 cells to determine wheth-
er membrane polarisation was changed by forskolin or DDF.
Control cells accumulated 2511 ± 201 pmol [3H]-TPP+/mg
cellular protein at 2 h, but the uptake was unaffected by the
diterpenes. These results indicated that the diterpenes did not
nonspecifically alter membrane permeability.
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Figure 8 Cytotoxicity of DDF and forskolin in KB-GRC1 (0)
and KB-3-1 (@) cells. The cells were exposed to increasing
concentrations of drug continuously. Cytotoxicity was assessed
by clonogenic assay. Values are mean ± s.d. of 4-5 experiments.
Cytotoxic studies
The ability of the diterpenes to selectively augment VBL
uptake suggested that they would selectively enhance VBL
cytotoxicity in KB-GRCI cells. As shown in Figure 8, the
sensitivity of the KB cell lines to DDF and forskolin was
determined. Each cell line was more resistant to forskolin
than to DDF. A non-toxic concentration of 20JM of each
modulator was used for subsequent studies. Figure 9 illus-
trates the ability of DDF and forskolin to enhance the
cytotoxicity of VBL. In these experiments, KB-GRCI cells
were 27-fold resistant to VBL relative to KB-3-1 cells; the
IC50 values were 18.9 ± 4.5 and 0.7 ± 0.3 nM, respectively. In
KB-GRCI cells, DDF increased the sensitivity to VBL by
7-fold, whereas forskolin had a discernable 1.5-fold effect. In
contrast in KB-3-1 cells, neither DDF nor forskolin affected
the VBL dose response curve. Median effect analysis was
used to determine the nature of the interaction between DDF
and VBL in KB-GRCI cells. Median effect analysis yielded
CT20, C150 and C180 values of 0.21 ± 0.05, 0.20 ± 0.05 and
0.18 ± 0.04, respectively (n = 2). CI values less than 1
indicate synergy, thus there was a highly synergistic interac-
tion between DDF and VBL in the KB-GRCI cells.
Drug
Figure 7 Ability of 50 ;LM DDF to enhance the I h uptake of
radiolabelled 6 nM VBL, 1 lLM doxorubicin (DOX), 10 nM
methotrexate (MTX) or 51M DEP in KB cells. Control pmol
drug accumulated mg-' cellular protein for each drug is shown in
parentheses. Values are mean ± s.d. of 2-5 experiments.
Discussion
In this report, we demonstrate that the diterpene analogues,
and notably DDF, selectively modulate VBL uptake, efflux
and sensitivity in tumour cells over-expressing mdrl. These
data demonstrate the feasibility ofmodulating sensitivity to a
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Figure 9 Clonogenic assay of vinblastine sensitivity in the presence of DDF and forskolin. KB-GRCI cells were exposed to
increasing concentrations of VBL alone (0), or to increasing concentrations of VBL in the presence of 20ylM DDF (A) or
forskolin (0). KB-3-l cells were exposed to VBL alone (0), or to increasing concentrations of VBL in the presence of 201AM DDF
(A) or forskolin (M). Values are mean ± s.d. of three experiments (vertical bars, s.d.).
vinca alkaloid commonly used for the treatment of cancer.
These data, when viewed in context with a previous report
(Morris et al., 1991) establish inhibition of PGP-mediated
efflux as a primary mechanism.
Forskolin was chosen for investigation because it activates
protein kinase A indirectly (Laurenza et al., 1989) and altera-
tion of protein kinase A has been shown to alter drug
sensitivity (Abraham et al., 1990) and phosphorylation of
PGP (Meyers, 1989; Mellado & Horwitz, 1987). Forskolin
also interacts with membrane-spanning proteins, such as
adenylyl cyclase, and glucose and ion transporters, known to
be homologous to PGP (Morris et al., 1991; Krupinski et al.,
1989).
While PGP may be phosphorylated by protein kinase C
and other kinases (Fine et al., 1988; Hamada et al., 1987;
Staats et al., 1990), the effect of PKC-activation is typically a
decrease in the level of drug accumulated. We have
confirmed that phorbol-treatment leads to decreased VBL
uptake in KB-GRCI cells (Shalinsky and Howell, unpub-
lished data) suggesting that PGP-mediated efflux was
stimulated by the treatment. Thus, a similar role for cAMP
can be excluded because forskolin enhanced, not decreased,
VBL uptake. Further studies examining PKC were not pur-
sued since the diterpenes appear to selectively alter PKA
rather than PKC pathways (Robison et al., 1968; Laurenza et
al., 1989). However, the possibility that the diterpenes may
inhibit PKC-mediated pathways to enhance VBL uptake can
not be ruled out.
The approach was aimed instead at examining the involve-
ment of cAMP based on the fact that forskolin directly
activates adenylate cyclase and DDF does not (ibid., ibid.).
The data demonstrated that the diterpene augmentation of
VBL uptake occurred independently of at least the protein
kinase A pathway since DDF was the most potent
modulator. This was supported by the lack of direct effect of
dibutyryl cAMP on [3H]-VBL uptake. These data lend sup-
port to the cAMP-independent mechanism initially pos-
tulated by Wadler & Wiernik (1988), but discount a direct
role for a cAMP-dependent mechanism that may modulate
PGP efflux activity at the level of the transporter itself. It
therefore appears that the PKA pathway may play a promi-
nent role in regulating the expression (Abraham et al., 1990)
but not the direct activity of PGP.
Comparison offorskolin and DDF as modulators
DDF was more potent than forskolin in enhancing uptake
and was selectively active in KB-GRCl cells. The greater
increase, 13.6-fold vs 1.4-fold in KB-3-1 cells, suggested that
DDF interacted directly with PGP to inhibit efflux activity.
The selective inhibition of efflux in KB-GRCI cells confirmed
this. The same rank order for relative lipophilicity and ability
to enhance VBL uptake was in good agreement with the
ability of these agents to inhibit photolabelling of PGP (Mor-
ris et al., 1991).
The hypothesis that VBL is a better substrate for PGP
than doxorubicin in KB-GRCl cells is substantiated by the
fact that KB-GRC1 cells are 7-fold more resistant to VBL
than doxorubicin (Choi et al., 1988). Furthermore, while
VBL may not universally be a superior substrate of PGP
compared to doxorubicin, VBL has been reported to inhibit
the labelling of PGP by azidopine to a greater extent than
doxorubicin in some MDR cell lines (Greenberger et al.,
1990). Thus, our results support previously published reports.
Modulation ofinflux and uptake
An ability of PGP to efflux drug during the initial seconds of
exposure has been established in KB-GRCI (Shalinsky et al.,
1993) and other MDR tumour cells (Cano-Gauci et al.,
1990). Initial VBL influx (< 120 s) in KB-GRCI cells is
energy-dependent and immediately potentiated by dipyrid-
amole and verapamil (Shalinsky et al., 1993), indicating the
presence of PGP's rapid efflux activity. Furthermore, DDF
has been shown to inhibit PGP-associated chloride channel
activity within 30 s of exposure (Valverde et al., 1992), sub-
stantiating that diterpene modulators can rapidly alter PGP
function.
These diterpenes also produced increases in the rate con-
stant for influx in KB-3-1 cells which would not be associated
with PGP, but for which non-specific mechanisms have been
largely excluded. It is possible that intracellular processes478 D.R. SHALINSKY et al.
unrelated to membrane permeability were affected. Thus,
these data implicated PGP-independent mechanisms which
remain unknown.
However, the enhanced influx in KB-3-1 cells was not
accompanied by large increases in the 1 h uptake, and thus it
is unlikely that DDF and forskolin will be as active against
drug-sensitive neoplasms. MDR modulators such as dipyrid-
amole, verapamil and DDF produce high levels of synergy
with VBL only in mdrl-over-expressing cells (Shalinsky et al.,
1990a; Shalinsky et al., 1991). Hence the relatively large
increase in the uptake in KB-GRC1 compared to KB-3-1
cells may represent the cytotoxically-relevant parameter for
producing synergy.
Modulation ofefflux
As discussed, DDF inhibited the initial efflux rate constant
for VBL in both KB-GRCl and KK cells, demonstrating
selective inhibition of PGP-mediated efflux. Of note is the
small effect on inhibition of initial efflux as compared to
enhancement of uptake. This seems to be a general
phenomenon. We have reported that dipyridamole and
verapamil have very small effects on inhibiting efflux com-
pared to their ability to enhance uptake (Shalinsky et al.,
1993). Similarly, phenoxazine modulators have large effects
on uptake but only <30% effects on inhibiting initial efflux
(Thimmaiah et al., 1990). These data suggest that some
factor may hinder the ability of the efflux blocker to exert its
effect when the membrane or cytoplasm is saturated with the
blocker, but the basis for this observation is unclear. Thus,
the small effects on efflux observed in this study were consis-
tent with other reports. It may therefore not be surprising
that forskolin failed to significantly inhibit initial influx in
lieu of its smaller ability to enhance uptake vs DDF, and due
to the fact that forskolin is a poorer antagonist of the
photolabelling of PGP relative to DDF (Morris et al., 1991).
DDF and forskolin inhibited terminal efflux more pro-
minently in cells irrespective of expression of mdrl, yet there
was no evidence for a change in the tightly-bound fraction of
VBL. Every MDR modulator we have studied produces a
similar pattern (Shalinsky et al., 1993; unpublished data), and
it would be of great interest to elucidate the mechanism(s).
The mechanism(s) responsible for this effect remains to be
determined.
Selective modulation ofcytotoxicity
The ability of forskolin and DDF to enhance the uptake of
VBL translated into a measurable increase in cytotoxicity
selectively in the KB-GRCI cell line. The enhanced cytotox-
icity mirrored well the ability of forskolin and DDF to
augment VBL uptake and to inhibit photolabelling of PGP
(Morris et al., 1991). Median effect analysis demonstrated a
highly synergistic interaction between VBL and DDF when
cytotoxic concentrations of DDF were used. Similar testing
was not done in KB-3-1 cells since in the absence of an effect
on C., synergy was unlikely, and only additive effects have
been observed between MDR modulators and VBL in
previous studies in KB-3-1 cells (Shalinsky et al., 1990).
Forskolin may have been expected to produce less synergy
with VBL than DDF, but prohibitive amounts of forskolin
would have been required and thus these experiments were
not done. Thus, DDF produced a large increase in sensitivity
to VBL, and the synergistic nature was encouraging with
regard to potential clinical utility.
Lipophilic diterpenes aspotential MDR chemosensitisers.
DDF compared favourably with dipyridamole and verapamil
in terms of its potency for enhancing the uptake of [3H]-VBL.
The EC50 for DDF was 15YM, and it was 5 and 28lAM for
dipyridamole and verapamil, respectively (Shalinsky et al.,
1990a). On the other hand, the maximum stimulation of
10.8 ± 0.3 pmol VBL mg-' cellular protein by DDF at
100l.M was higher than for other agent tested to date in
KB-GRC1 cells. For example, a saturating concentration of
80 !LM dipyridamole and verapamil elevated the Cs. of [3H]-
VBL to 6.2 ± 0.8 and 4.6 ± 0.6 pmol mg-1, respectively
(Shalinsky et al., 1990a). Despite the larger effect of DDF on
uptake, DDF produced a similar level of synergy with VBL
as compared to that observed in combination with dipyrid-
amole or verapamil (Shalinsky et al., 1990a), but it
must be noted that all three agents produced about the
maximum level of synergy that can be obtained by median
effect analysis (CI50 values <0.2). We can therefore conclude
that each produced an excellent level of synergy in combina-
tion with VBL. Thus, DDF compared favourably at the in
vitro level in its ability to modulate VBL toxicity. It remains
to be determined whether DDF or another lipophilic
diterpene will prove to be a superior chemosensitiser, and in
vivo studies are needed to address this point. There is limited
data available regarding efficacy or toxicity in vivo and none
of the diterpenes studied herein have been approved for
human use (K. Seamon, personal communication). One may
reasonably expect, though, that DDF would lack the car-
diotoxic side effects that limit the use of verapamil, and that
lack of an effect on the cAMP pathway may also be an
advantage.
Conclusions
This report definitively links the ability of DDF to inhibit
PGP-mediated effilux with enhancement of VBL sensitivity.
DDF produced a selective enhancement of accumulation of
[3H]-VBL and sensitivity to VBL resulting in a high level of
synergy with VBL in cells over-expressing mdrl. These effects
were related to lipophilicity but were unrelated to cAMP.
Thus, our data, along with previous reports (Morris et al.,
1991; Wadler & Wiernik, 1988), suggest that the class of
lipophilic diterpene analogues may be good candidates for
further study as potential MDR chemosensitisers in the
anticancer therapy.
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